Lu sur : https://www.ncbi.nlm.nih.gov/pubmed/31250577
Traduction disponible directement en cliquant en bas à droite de ce message sur l'expression Traduire en
Yonsei Med J. 2019 Jul;60(7):633-639. doi: 10.3349/ymj.2019.60.7.633.
Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis.
Kim YH1, Shin HY2, Kim SM3.
Myasthenia gravis (MG) is a lifelong autoimmune disorder that affects neuromuscular transmission. The long-term treatment plan should include immunotherapy. We investigated the long-term safety and efficacy of tacrolimus for the treatment of MG in real-world clinical practice.
MATERIALS AND METHODS:
We retrospectively reviewed 160 MG patients treated with tacrolimus from 2005 to 2015. Myasthenia Gravis Foundation of America (MGFA) clinical classification, MGFA post-intervention status, myasthenic functional score, and dose of oral prednisolone were investigated.
Adverse events occurred in 68 patients (42.5%), most of which were minor and well-managed. Clinical severity scales improved after administration of tacrolimus, compared to the baseline. Compared to 6 months before administration of tacrolimus, prednisolone dose significantly decreased at 12 months after treatment (2.85±0.92 mg/day, p=0.002), 18 months after treatment (3.36±0.99 mg/day, p=0.001), and 24 months after treatment (3.71±0.93 mg/day, p<0.001).
Tacrolimus may be effective in reducing the severity of MG and may permit a reduction in the steroid dose prescribed to the patients. Adverse events due to tacrolimus treatment were not serious.
Article intégral disponible pour nos donateurs